Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 20, 2023 08:00 ET | Source: Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)

LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical...